Abstract 4787
Background
Comparison of options from clinical decision-support (CDS) systems and decisions made in practice may be biased towards the treating institution. In this retrospective study, bias was minimized by blinding evaluators to the source of treatment recommendations, either Watson for Oncology® (WFO®) or treatments patients received at Bumrungrad International Hospital (BIH), a user of WFO®.
Methods
Treatments given were compared to therapeutic options provided by WFO®. Treatments that were identical to WFO® “recommended” (green, acceptable) were not evaluated further. Paired treatments were evaluated independently in a blinded fashion by each oncologist before consensus ranking of each pair as either acceptable, acceptable alternatives, or unacceptable treatment. The consensus for each treatment was compared to WFO®, with WFO® “for consideration” (yellow, acceptable alternative), and “not recommended” (red, unacceptable). Chi-squared tests analyzed the association between risk factors and discordant recommendations.
Results
Of 228 treatments given to patients with lung, colon, breast and rectal cancers, 174 were identical to WFO® acceptable (green) and not evaluated further; 54 non-identical pairs were evaluated (Table). Overall, 88.6% of decisions were either the same or viewed as equally acceptable by oncologists; oncologists preferred 3.9% of BIH treatments and 4.4% of WFO treatments. In cases where reasons for discordance were provided, 70% were due to BIH oncologist preference, 20% to patient preference and 10% to WFO treatment availability. We found no association between discordant recommendations and patient age or stage of cancer.Table: 1435P
Treatments | N (%) 228 Total |
---|---|
Treatments are identical | 174 (76.3%) |
Oncologists’ Evaluations | |
Acceptable alternatives | 28 (12.3%) |
BIH Preferred | 9 (3.9%) |
WFO Preferred | 10 (4.4%) |
Both WFO and BIH-Rx unacceptable | 7 (3.1%) |
Conclusions
This blinded study suggests WFO®’s therapeutic options are at as least as good as (or are an acceptable alternative to) treatments in practice. Blinding evaluators to source of treatment may minimize bias in comparisons of CDS systems and decisions made in practice.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Bumrungrad International Hospital.
Funding
Bumrungrad International Hospital.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3047 - Health-related quality of life in Greek haematogical malignancies patients undergoing chemotherapy
Presenter: Maria Lavdaniti
Session: Poster Display session 3
Resources:
Abstract
1121 - Experiences of endocrine therapy after breast cancer surgery
Presenter: Susanne Ahlstedt Karlsson
Session: Poster Display session 3
Resources:
Abstract
2305 - The effects of progressive muscle relaxation and mindfulness meditation on fatigue, coping styles, and quality of life in breast cancer patients receiving adjuvant paclitaxel regimen: An-assessor blinded, three-arm randomized controlled trial
Presenter: Zehra Gok Metin
Session: Poster Display session 3
Resources:
Abstract
4561 - Agreement between breast cancer patients and oncologists on the severity of patients’ symptoms and functions during a one-year follow-up after treatment.
Presenter: Randi Reidunsdatter
Session: Poster Display session 3
Resources:
Abstract
1768 - Taste Changes and Associated Factors in Patients Receiving Chemotherapy
Presenter: Gulcan Bagcivan
Session: Poster Display session 3
Resources:
Abstract
1830 - CART-19: a comparative between literature versus experience
Presenter: Cassandra Andersson Vila
Session: Poster Display session 3
Resources:
Abstract
4027 - Unplanned emergency department use by people receiving ambulatory anti-cancer agents with potential febrile neutropenia
Presenter: Meritxell Casanovas-Blanco
Session: Poster Display session 3
Resources:
Abstract
4754 - Examining the benefits of medical exercise during radiotherapy in patients after mastectomy
Presenter: Nikolina Dodlek
Session: Poster Display session 3
Resources:
Abstract
2510 - Assessment Quality of Life with Hand-Foot Syndrome Induced by Apatinib Combined with Anti-PD-1 Therapy in NSCLC
Presenter: Qi Jiang
Session: Poster Display session 3
Resources:
Abstract
2989 - Adverse effects of chemotherapy influence the patients’ quality of life : Analysis of implicated factors
Presenter: Maria Lavdaniti
Session: Poster Display session 3
Resources:
Abstract